CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Rating)’s stock price was down 5.5% during trading on Monday . The company traded as low as $0.21 and last traded at $0.23. Approximately 329,537 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 1,003,372 shares. The stock had previously closed at $0.24.
Analyst Upgrades and Downgrades
Separately, Maxim Group cut shares of CNS Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 17th.
CNS Pharmaceuticals Stock Down 5.5 %
The business’s 50-day moving average is $0.24 and its two-hundred day moving average is $0.29. The company has a market capitalization of $9.01 million, a P/E ratio of -0.56 and a beta of 1.33.
Institutional Trading of CNS Pharmaceuticals
CNS Pharmaceuticals Company Profile
CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme.
- Get a free copy of the StockNews.com research report on CNS Pharmaceuticals (CNSP)
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.